New treatments for chronic hepatitis B using long-acting medications
Official title: New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
Funded at University of Nebraska Medical Center · NIH-11042702 · Data updated 2026-11-12
This study is testing a new type of long-lasting injection for people with chronic hepatitis B that could replace daily pills, making treatment easier and more effective by combining special medications to help your body fight the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | March 10, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $611,174 |
| NIH project number | 5R01AI163042-04 |
| Project ID | NIH-11042702 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic hepatitis B who are currently on antiviral therapy or are in need of treatment.
✕Less likely to help
Patients who do not have chronic hepatitis B or those who are not eligible for antiviral therapy may not benefit from this research.
What this research studies
This research focuses on developing a new generation of long-acting injectable medications for chronic hepatitis B (CHB) that could replace the need for daily pills. By combining nucleos(t)ide analogs with immune-stimulating compounds, the goal is to create a treatment that can be administered every two months. The approach involves formulating these drugs into nanosuspensions to enhance their effectiveness and ensure they are absorbed efficiently by the liver. This innovative method aims to achieve sustained viral suppression and potentially a functional cure for CHB.
Why it matters
Potential benefit: If successful, this research could significantly improve the treatment of chronic hepatitis B, reducing the burden of the disease and its complications.
How similar studies have gone: Previous research has shown promise in using long-acting antiviral therapies for other conditions, suggesting potential success for this novel approach in chronic hepatitis B.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Poluektova, Larisa Y — University of Nebraska Medical Center
- Study coordinator: Poluektova, Larisa Y
Related research
Other NIH-funded projects on the same topics.
-
HBV immune responses in functional cure and therapies guided by CD4 T cells and B cells
This grant studies how HBV-specific CD4 T cells and B cells behave in people with hepatitis B to identify clues for achieving a functional cure.
-
Therapeutic nucleic acid vaccine for chronic hepatitis B in people with HIV/HBV co-infection
A new genetic vaccine approach is being tested to help people living with both HIV and chronic hepatitis B reduce and potentially cure their HBV infection.
-
HBV immune responses and pathways linked to functional cure
Researchers will study how HBV-specific CD4 T cells and B cells behave in people with chronic hepatitis B to find what immune changes are needed for a functional cure.
-
Nanobodies to help clear HBV surface antigen and restore immunity
A small, targeted antibody therapy using nanobodies is being explored to lower hepatitis B surface antigen in people with chronic HBV, with the goal of helping the immune system clear the infection.
-
How immune cells help control chronic hepatitis B
This research looks at how two immune cell types (CD4 T cells and B cells) in adults with hepatitis B act differently in people who clear the virus versus those with long-term infection to find clues for treatments that could lead to a functional cure.
-
Host-targeted antiviral to achieve a functional cure for chronic hepatitis B
A research project tests a new drug strategy that aims to clear signs of hepatitis B in people who have a chronic infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.